Successful use of weekly pegvisomant administration in patients with acromegaly.
AffiliationC Higham, Endocrinology, Christie Hospital, Manchester, M20 4BX, United Kingdom.
MetadataShow full item record
AbstractContext Clinical trials using 80 mg once-weekly pegvisomant in active acromegaly led to a 30% fall in serum IGF-I. Subsequent studies demonstrated that daily administration of up to 40 mg/day achieved an IGF-I within reference range in 97% of patients. Pegvisomant has a half-life of >70hrs suggesting weekly dosing may be possible but using higher doses than in the initial trials. Objective To determine the efficacy of weekly dosing of pegvisomant. Design A two-center, open-label prospective study in patients with acromegaly converted from a stable daily dose of pegvisomant (median dose 15 mg daily [range 10-20 mg od], IGF-I normal for 3 months prior to inclusion) to twice-weekly (week 0-16) followed by once-weekly (week 16-32) administration. Results Seven patients (4M, age 57+/-7 yrs, 6/7 prior trans-sphenoidal surgery, 7/7 prior radiotherapy) were recruited. Six patients completed the twice-weekly and five patients both the twice-weekly and once-weekly administration. Headaches led to 2 patient withdrawals at 0 + 24 weeks. Mean pre-dose serum IGF-I levels remained stable with the different administration regimens (IGF-I baseline 145+/-39 ng/ml, twice-weekly 124+/-39 ng/ml and once-weekly 127+/-22 ng/ml) and all values were within age adjusted IGF-I reference range. Pegvisomant dose was reduced in 2 patients and 5 opted to continue weekly administration at trial termination. Safety and QOL parameters remained stable. Conclusions Twice and once-weekly administration of pegvisomant is effective in controlling serum IGF-I levels in acromegaly and although not formally assessed, continuation of weekly dosing in 5 patients at study conclusion suggests patient preference for this regimen.
CitationSuccessful use of weekly pegvisomant administration in patients with acromegaly. 2009: Eur. J. Endocrinol.
JournalEuropean Journal of Endocrinology
- What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
- Authors: Muhammad A, van der Lely AJ, O'Connor RD, Delhanty PJ, Dal J, Dallenga AH, Feelders RA, Janssen JA, Jorgensen JO, Neggers SJ
- Issue date: 2016 May
- Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
- Authors: Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ, Jørgensen JO, van der Lely AJ
- Issue date: 2014 Oct
- Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
- Authors: Franck SE, van der Lely AJ, Delhanty PJ, Jørgensen JO, Neggers SJ
- Issue date: 2015 Nov
- The German ACROSTUDY: past and present.
- Authors: Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study.
- Issue date: 2009 Nov
- Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
- Authors: Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ
- Issue date: 2012 Apr